Apeloa Pharmaceutical Co.,Ltd

Shenzhen Stock Exchange 000739.SZ

Apeloa Pharmaceutical Co.,Ltd Debt to Equity Ratio for the year ending December 31, 2023: 0.13

Apeloa Pharmaceutical Co.,Ltd Debt to Equity Ratio is 0.13 for the year ending December 31, 2023, a -12.09% change year over year. Debt to equity ratio represents the financing from debt versus equity. Higher ratio indicates more debt reliance, suggesting potential risk.

Apeloa Pharmaceutical Co.,Ltd Debt to Equity Ratio for the year ending December 31, 2022 was 0.15, a 62.05% change year over year.
Apeloa Pharmaceutical Co.,Ltd Debt to Equity Ratio for the year ending December 31, 2021 was 0.09, a 24.62% change year over year.
Apeloa Pharmaceutical Co.,Ltd Debt to Equity Ratio for the year ending December 31, 2020 was 0.08, a 466.88% change year over year.
Apeloa Pharmaceutical Co.,Ltd Debt to Equity Ratio for the year ending December 31, 2019 was 0.01, a -92.77% change year over year.

Key data

Date	Debt to Equity Ratio	Debt to Income Ratio	Debt to Tangible Net Worth Ratio	Dividend Coverage Ratio

Shenzhen Stock Exchange: 000739.SZ

Apeloa Pharmaceutical Co.,Ltd

CEO	Mr. Fangmeng Zhu
IPO Date	May 9, 1997
Location	China
Headquarters	No. 333, Jiangnan Road
Employees	7,208
Sector	Health Care
Industries Pharmaceuticals

Description

Apeloa Pharmaceutical Co.,Ltd researches and develops, produces, and sells pharmaceutical products in China and internationally. It provides products in the cardio-cerebrovascular, anti-infection, anti-viral, anti-tumor, and other treatment areas. The company offers preparations, raw material intermediates, and veterinary drugs primarily under the Tianliwei, Beshin, Yosemade, Jutai, and other brands. It also provides contract research and development, and production services for pharmaceutical companies. The company is headquartered in Dongyang, China.

Key trends

Past 5 years